Abstract
Background
Recent studies suggested that administration of corticosteroids may improve clinical outcomes in patients with severe pneumonia.
Objectives
The aim of this study was to assess the effectiveness of corticosteroids as an adjunctive therapy in community-acquired pneumonia (CAP) requiring hospitalization.
Design and Setting
An open label, prospective, randomized control study was conducted from September 2003 to February 2004 in a community general hospital in Japan.
Patients
Thirty-one adult CAP patients who required hospitalization were enrolled.
Measurements and Results
Fifteen patients received 40 mg of prednisolone intravenously for 3 days (steroid group). Sixteen patients did not receive prednisolone (control group). Both groups were also evaluated for their adrenal function. The primary endpoint was length of hospital stay. Secondary endpoints were duration of intravenous (IV) antibiotics and time required to stabilize vital signs. Both groups demonstrated similar baseline characteristics and length of hospital stay, and yet a shorter duration of IV antibiotics was observed in the steroid group (p < 0.05). In addition, vital signs were stabilized earlier in the steroid group (p < 0.05). These differences were more prominent in the moderate–severe subgroup but not as significant in the mild–moderate subgroup. The prevalence of relative adrenal insufficiency (RAI) in both groups was high (43%), yet there was no difference in baseline characteristics between patients, with or without RAI. In multiple regression models, RAI seemed to have no influence on clinical courses.
Conclusions
In moderate–severe CAP, administration of corticosteroids promotes resolution of clinical symptoms and reduces the duration of intravenous antibiotic therapy.
Similar content being viewed by others
Abbreviations
- CAP:
-
Community-acquired pneumonia
- RAI:
-
Relative adrenal insufficiency
- PSI:
-
Pneumonia severity index
- PORT:
-
Pneumonia Patient Outcomes Research Team
References
Health and Welfare Statistics Association of Japan (2004) Annual Report of National Health and Hygiene in Japan. Kouseinoshihyou 51:382–385 [in Japanese]
Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Eng J Med 333:1618–1624
Stahl JE, Barza M, DesJardin, Martin R, Eckman MH (1999) Effect of macrolides as part of initial antibiotic therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 159:2576–2580
Gleason PP, Meeham TP, Fine JM, Galusha DH, Fine MJ (1999) Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 159:2562–2572
Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–2084
Ramirez JA, Bordon J (2001) Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 161:848–850
National Institutes of Health / National Heart Lung, Blood Institute (2002) Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publ 02–3659
Hurd S, Pauwels R (2002) Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Pulm Pharmacol Ther 15:353–355
Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732
Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
Lebel MH, Freij BJ, Syrogiannopoulos GA, Chrane DF, Hoyt MJ, Stewart SM, Kennard BD, Olsen KD, McCracken GH Jr (1988) Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 319:964–971
de Gans J, van de Beek D (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347:1549–1556
Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rano A, Xaubet A (1999) Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 14:218–220
Confalonieri M, Urbino R, Potena A, Piattella M, Pariqi P, Puccio G, Della Porta R, Giorqio C, Blasi F, Umberqer R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia. Am J Respir Crit Care Med 171:242–248
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
Cooper MS, Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348:727–734
Slutsky AS, Tremblay LN (1998) Multiple system organ failure. Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med 157:1721–1725
Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA (1999) Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340:1941–1947
Bach PB, Brown C, Gelfand SE, McCrory DC (2001) American College of Physicians–American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 134:600–620
File TM Jr (2004) Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39:S159–S164
Mandell LA, File TM Jr (2003) Short-course treatment of community-acquired pneumonia. Clin Infect Dis 37:761–763
Sibille Y, Reynolds HY (1990) Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 141:471–501
Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M (1994) Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 150:710–716
Puren AJ, Feldman C, Savage N, Becker PJ, Smith C (1995) Patterns of cytokine expression in community-acquired pneumonia. Chest 107:1342–1349
Maus U, Rosseau S, Knies U, Seeger W, Lohmeyer J (1998) Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia. Eur Respir J 11:534–541
Marik PE, Zaloga GP (2002) Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 122:1784–1796
Salluh JI, Verdeal JC, Mello GW, Araujo LV, Martins GA, de Sousa Santino M, Soares M (2006) Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 32:595–598
Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mikami, K., Suzuki, M., Kitagawa, H. et al. Efficacy of Corticosteroids in the Treatment of Community-Acquired Pneumonia Requiring Hospitalization. Lung 185, 249–255 (2007). https://doi.org/10.1007/s00408-007-9020-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-007-9020-3